New Two-Drug attack tested for Tough-to-Treat lung cancer
NCT ID NCT05570825
Summary
This study is testing if a new drug, SX-682, works better when given with an existing immunotherapy drug (pembrolizumab) for people with advanced non-small cell lung cancer that has spread or come back. The goal is to see if this combination can help the body's immune system fight the cancer more effectively. About 30 people will take the two drugs together to check for safety and see if their tumors shrink.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.